These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

394 related items for PubMed ID: 18033231

  • 1. Risk stratification of sudden cardiac death in hypertrophic cardiomyopathy.
    Miller MA, Gomes JA, Fuster V.
    Nat Clin Pract Cardiovasc Med; 2007 Dec; 4(12):667-76. PubMed ID: 18033231
    [Abstract] [Full Text] [Related]

  • 2. [Evaluation of the risk of sudden death in hypertrophic cardiomyopathy].
    Sadoul N, de Chillou C, Aliot E, McKenna WJ.
    Arch Mal Coeur Vaiss; 1999 Apr; 92 Spec No 1():65-73. PubMed ID: 10326160
    [Abstract] [Full Text] [Related]

  • 3. Characteristics and clinical significance of late gadolinium enhancement by contrast-enhanced magnetic resonance imaging in patients with hypertrophic cardiomyopathy.
    Rubinshtein R, Glockner JF, Ommen SR, Araoz PA, Ackerman MJ, Sorajja P, Bos JM, Tajik AJ, Valeti US, Nishimura RA, Gersh BJ.
    Circ Heart Fail; 2010 Jan; 3(1):51-8. PubMed ID: 19850699
    [Abstract] [Full Text] [Related]

  • 4. Hypertrophic cardiomyopathy--state of the art in 2007.
    Monteiro S, Costa S, Monteiro P, Gonçalves L, Providência LA.
    Rev Port Cardiol; 2008 May; 27(5):625-37. PubMed ID: 18717215
    [Abstract] [Full Text] [Related]

  • 5. Risk factors and mode of death in isolated hypertrophic cardiomyopathy in children.
    Decker JA, Rossano JW, Smith EO, Cannon B, Clunie SK, Gates C, Jefferies JL, Kim JJ, Price JF, Dreyer WJ, Towbin JA, Denfield SW.
    J Am Coll Cardiol; 2009 Jul 14; 54(3):250-4. PubMed ID: 19589438
    [Abstract] [Full Text] [Related]

  • 6. A validation study of the 2003 American College of Cardiology/European Society of Cardiology and 2011 American College of Cardiology Foundation/American Heart Association risk stratification and treatment algorithms for sudden cardiac death in patients with hypertrophic cardiomyopathy.
    O'Mahony C, Tome-Esteban M, Lambiase PD, Pantazis A, Dickie S, McKenna WJ, Elliott PM.
    Heart; 2013 Apr 14; 99(8):534-41. PubMed ID: 23339826
    [Abstract] [Full Text] [Related]

  • 7. Utility of microvolt T-wave alternans to predict sudden cardiac death in patients with cardiomyopathy.
    Chauhan VS, Selvaraj RJ.
    Curr Opin Cardiol; 2007 Jan 14; 22(1):25-32. PubMed ID: 17143041
    [Abstract] [Full Text] [Related]

  • 8. [Cardiomyopathies. VIII. Sudden death in hypertrophic cardiomyopathy].
    Alfonso F.
    Rev Esp Cardiol; 1996 Apr 14; 49(4):288-304. PubMed ID: 8650406
    [Abstract] [Full Text] [Related]

  • 9. Disease penetrance and risk stratification for sudden cardiac death in asymptomatic hypertrophic cardiomyopathy mutation carriers.
    Michels M, Soliman OI, Phefferkorn J, Hoedemaekers YM, Kofflard MJ, Dooijes D, Majoor-Krakauer D, Ten Cate FJ.
    Eur Heart J; 2009 Nov 14; 30(21):2593-8. PubMed ID: 19666645
    [Abstract] [Full Text] [Related]

  • 10. Sudden cardiac arrest in a young patient with hypertrophic cardiomyopathy and zero canonical risk factors: the inherent limitations of risk stratification in hypertrophic cardiomyopathy.
    Kohorst JJ, Bos JM, Hagler DJ, Ackerman MJ.
    Congenit Heart Dis; 2014 Nov 14; 9(2):E51-7. PubMed ID: 23648018
    [Abstract] [Full Text] [Related]

  • 11. Implantable cardioverter-defibrillator therapy for primary prevention of sudden death after alcohol septal ablation of hypertrophic cardiomyopathy.
    Cuoco FA, Spencer WH, Fernandes VL, Nielsen CD, Nagueh S, Sturdivant JL, Leman RB, Wharton JM, Gold MR.
    J Am Coll Cardiol; 2008 Nov 18; 52(21):1718-23. PubMed ID: 19007692
    [Abstract] [Full Text] [Related]

  • 12. Sudden death and hypertrophic cardiomyopathy: a review.
    Ly HQ, Greiss I, Talakic M, Guerra PG, Macle L, Thibault B, Dubuc M, Roy D.
    Can J Cardiol; 2005 Apr 18; 21(5):441-8. PubMed ID: 15861263
    [Abstract] [Full Text] [Related]

  • 13. Noninvasive risk stratification prevents sudden death due to paroxysmal atrial fibrillation in hypertrophic cardiomyopathy.
    Limongelli G, Elliott PM, Pacileo G, Sarubbi B, Thaman R, Calabrò P, Vergara P, Iacomino M, Russo MG, Calabrò R.
    J Cardiovasc Med (Hagerstown); 2006 Sep 18; 7(9):711-3. PubMed ID: 16932087
    [Abstract] [Full Text] [Related]

  • 14. Microvolt T-wave alternans testing for ventricular arrhythmia risk stratification.
    Chow T, Joshi D.
    Expert Rev Cardiovasc Ther; 2008 Jul 18; 6(6):833-42. PubMed ID: 18570621
    [Abstract] [Full Text] [Related]

  • 15. Life expectancy gains and cost-effectiveness of implantable cardioverter/defibrillators for the primary prevention of sudden cardiac death in patients with hypertrophic cardiomyopathy.
    You JJ, Woo A, Ko DT, Cameron DA, Mihailovic A, Krahn M.
    Am Heart J; 2007 Nov 18; 154(5):899-907. PubMed ID: 17967596
    [Abstract] [Full Text] [Related]

  • 16. Hypertrophic cardiomyopathy and other causes of sudden cardiac death in young competitive athletes, with considerations for preparticipation screening and criteria for disqualification.
    Maron BJ.
    Cardiol Clin; 2007 Aug 18; 25(3):399-414, vi. PubMed ID: 17961794
    [Abstract] [Full Text] [Related]

  • 17. Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy.
    Chan RH, Maron BJ, Olivotto I, Pencina MJ, Assenza GE, Haas T, Lesser JR, Gruner C, Crean AM, Rakowski H, Udelson JE, Rowin E, Lombardi M, Cecchi F, Tomberli B, Spirito P, Formisano F, Biagini E, Rapezzi C, De Cecco CN, Autore C, Cook EF, Hong SN, Gibson CM, Manning WJ, Appelbaum E, Maron MS.
    Circulation; 2014 Aug 05; 130(6):484-95. PubMed ID: 25092278
    [Abstract] [Full Text] [Related]

  • 18. Risk assessment and prevention of sudden cardiac death in hypertrophic cardiomyopathy.
    Slade AK, Camm AJ.
    Arch Mal Coeur Vaiss; 1996 Feb 05; 89 Spec No 1():37-49. PubMed ID: 8734163
    [Abstract] [Full Text] [Related]

  • 19. Usefulness of cardiac magnetic resonance in assessing the risk of ventricular arrhythmias and sudden death in patients with hypertrophic cardiomyopathy.
    Leonardi S, Raineri C, De Ferrari GM, Ghio S, Scelsi L, Pasotti M, Tagliani M, Valentini A, Dore R, Raisaro A, Arbustini E.
    Eur Heart J; 2009 Aug 05; 30(16):2003-10. PubMed ID: 19474054
    [Abstract] [Full Text] [Related]

  • 20. The pathology of hypertrophic cardiomyopathy.
    Hughes SE.
    Histopathology; 2004 May 05; 44(5):412-27. PubMed ID: 15139989
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.